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Abstract
Precise knowledge regarding cellular uptake of nanoparticles is of great importance for future biomedical applications. Four
different endocytotic uptake mechanisms, that is, phagocytosis, macropinocytosis, clathrin- and caveolin-mediated endocytosis,
were investigated using a mouse macrophage (J774A.1) and a human alveolar epithelial type II cell line (A549). In order to deduce
the involved pathway in nanoparticle uptake, selected inhibitors specific for one of the endocytotic pathways were optimized
regarding concentration and incubation time in combination with fluorescently tagged marker proteins. Qualitative immunolocaliza-
tion showed that J774A.1 cells highly expressed the lipid raft-related protein flotillin-1 and clathrin heavy chain, however, no
caveolin-1. A549 cells expressed clathrin heavy chain and caveolin-1, but no flotillin-1 uptake-related proteins. Our data revealed
an impeded uptake of 40 nm polystyrene nanoparticles by J774A.1 macrophages when actin polymerization and clathrin-coated pit
formation was blocked. From this result, it is suggested that macropinocytosis and phagocytosis, as well as clathrin-mediated endo-
cytosis, play a crucial role. The uptake of 40 nm nanoparticles in alveolar epithelial A549 cells was inhibited after depletion of
cholesterol in the plasma membrane (preventing caveolin-mediated endocytosis) and inhibition of clathrin-coated vesicles
(preventing clathrin-mediated endocytosis). Our data showed that a combination of several distinguishable endocytotic uptake
mechanisms are involved in the uptake of 40 nm polystyrene nanoparticles in both the macrophage and epithelial cell line.
Introduction
In recent years, the use of engineered nanoparticles (NPs)
(defined as <100 nm in three dimensions according to ISO TS
27687:2008) has witnessed a strong rise in biomedical and
pharmaceutical applications, specifically for targeted drug
delivery [1-6], biosensing [7] and bio-medical imaging [8]. In
order to develop optimal NPs for biomedical use, much atten-
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tion is given to the understanding of the basic mechanism of NP
interactions with cellular systems at the single cellular level
[9-11]. It has already been shown that different NP properties,
such as size, shape, material and surface coating, as well as the
cell type, age, interaction with other cells and the cellular envi-
ronment, influence NP uptake and the cellular behavior as well
as the down-stream response of the cells [11-16].
The term endocytosis describes two different cellular uptake
mechanisms: pinocytosis, which involves the uptake of fluids
and molecules within small vesicles and phagocytosis, which is
responsible for engulfing large particles (e.g., microorganisms
and cell debris). Pinocytosis covers macropinocytosis, clathrin-
mediated endocytosis, caveolin-mediated endocytosis and
clathrin- and caveolin-independent endocytosis [8,17-20].
However, not all cell types are equipped with the required
machinery to perform the entire spectrum of endocytotic path-
ways. Therefore, these pathways are specific to types of cells
and subsequently determine the trafficking and intracellular fate
of particles [21]. Red blood cells are a common example, as
they do not have any phagocytic receptors on their surface and
no actin–myosin system, therefore they serve as a model for
non-phagocytic cells to study how NPs penetrate through cell
membranes [22].
Phagocytosis and macropinocytosis are both dependent on actin
[15,23]. Phagocytosis is carried out by professional phagocytes
(i.e., monocytes/macrophages, neutrophils and dendritic cells),
which in turn form intracellular phagosomes. Macromolecule
and particle uptake is triggered via the interaction of the
responsible receptors on the cell surface and the ligands.
Macropinocytosis, which is also actin-driven, forms protru-
sions at the outer cell membrane which then again fuse with the
cell membrane by taking up larger fragments or debris [14].
Clathrin-mediated endocytosis is very well studied and is, like
most pinocytotic pathways, a form of receptor-mediated endo-
cytosis. This abundant pathway is essential for the uptake of
many molecules such as low-density lipoprotein and transferrin
[24,25]. When clathrin-mediated endocytosis is initiated, the
so-called “coated pits” come into play consisting of transmem-
brane receptors and cytosolic proteins, such as clathrin and the
AP2 adaptor complex [20].
On the other hand, caveolin-mediated endocytosis is respon-
sible for the homeostasis of cholesterol [20]. The static struc-
tures of caveolae form flask-shaped invaginations in the cell
membrane. Many cell types such as the capillary endothelium,
type I epithelial cells, muscle cells as well as fibroblasts, ex-
hibit caveolin-mediated endocytosis, which occurs at the site of
the lipid rafts [20,26]. These rafts are plasma membrane regions
(subdomains), which consist of glycosphingolipids and high
amounts of cholesterol [27]. The protein which gives shape and
structure in caveolin-mediated endocytosis is caveolin-1, a
dimeric protein which binds cholesterol onto the cellular surface
for uptake and intracellular trafficking (lipid homeostasis) [28].
Also located at the site of lipid rafts is flotillin-1, an integral
membrane protein which forms a hetero-oligomer with
flotillin-2 [29]. In addition to the aforementioned uptake mecha-
nisms, clathrin- and caveolin-independent endocytosis as well
as passive diffusion of NPs across the cell plasma membrane
are also addressed [17,30].
To elaborate on the most important cellular endocytotic uptake
mechanism of NPs, specific pharmacological substances which
inhibit specific pathways can be used [31]. It is important to
highlight that the use of inhibitors must be optimized for each
cell and NP type, since an inhibitor might show a high speci-
ficity in one experiment but cause side effects in another [32].
The use of positive controls to show that an inhibitor only
affects one endocytotic pathway without interfering with other
uptake mechanism(s) is mandatory [33]. There are many
different inhibitors described, and we will focus only on the
most commonly used drugs to study NP uptake.
Cytochalasin D can depolymerize actin filaments [34,35] and
can therefore be used to study actin-dependent uptake mecha-
nisms, that is, phagocytosis and macropinocytosis. Larger parti-
cles, such as polystyrene particles of 1 µm in diameter, can be
used to run the experiment under controlled conditions.
Chlorpromazine hydrochloride which inhibits clathrin-medi-
ated endocytosis, induces a loss of clathrin and adaptor protein
complex 2 from the surface of the cell [31,36]. It is thus classi-
fied as an inhibitor for clathrin-mediated endocytosis [37,38].
Monodansylcadaverine (MDC), a competitive inhibitor, blocks
the enzyme transglutaminase 2, which is necessary for receptor
crosslinking in the region of clathrin-coated pits [31,39,40].
Furthermore, chlorpromazine and MDC are specific in
inhibiting the uptake of the serum protein transferrin [41].
Consequently, fluorescently labelled transferrin can be used to
investigate clathrin-mediated endocytosis [32,41,42].
Caveolae and lipid raft internalizations are known to be inhib-
ited by nystatin, filipin and methyl-β-cyclodextrin (mβcd)
through depletion of the cholesterol from the cell membrane by
forming inclusion complexes with cholesterol [31,43]. It was
also shown that mβcd inhibits clathrin-mediated endocytosis,
since clathrin uptake requires cholesterol as well [11,44]. All of
these mentioned inhibitors form aggregates which accumulate
cholesterol and separate it from the membrane structures.
Finally, the cholera toxin subunit b (ctx-b) [45] has been shown
Beilstein J. Nanotechnol. 2014, 5, 1625–1636.
1627
Figure 1: Characterization of polystyrene particles. (A) Characteristics of the particles as measured by dynamic light scattering, zeta potential and
transmission electron microscopy in water and unsupplemented cell culture medium. Transmission electron microscopy images of (B) 1 µm particles,
(C) NPs, and (D) a mixture of 1 µm particles and NPs.
to enter the cells by caveolin-mediated endocytosis, therefore
this protein can be used to control the inhibitors in any experi-
mental setting.
To show that the endocytotic uptake route of choice is depen-
dent upon the particle size, we deployed two fluorescently
labelled polystyrene particles of significantly different sizes,
that is, 40 nm and 1 µm in diameter. These particles were
chosen as they are easy to detect by fluorescence methods and
available in different sizes [46]. Moreover, they have a narrow
size distribution and are considered to be suitable for biomed-
ical applications [47,48] since they are considered non-toxic at
applied physiological concentrations [49]. Finally, two of the
most relevant cell types in regard to uptake and interaction of
(nano) particles at any barrier system (i.e., macrophages and
epithelial) [50,51] were included to demonstrate that not only
the applied particle dimensions and uptake pathways are deter-
minant, but the actual cell types as well.
Results
Particle characterization
In the first step, both particles were thoroughly investigated
prior to cellular experiments. The particle size measured with
dynamic light scattering (DLS) revealed an average hydrody-
namic radius of approximately 581 nm for the microparticles
and 28 nm for the nanoparticles. Transmission electron
microscopy (TEM) revealed a core radius of 520 nm for the
microparticles and 30.9 nm for the NPs. The latter, however,
exhibited a larger polydispersity (Figure 1). Both methods
confirm the experimentally obtained values. Measurements
were carried out in water and unsupplemented RPMI medium
and showed that all analyzed particles remained stable and
monodisperse in biological medium. The zeta potential indi-
cated a negative charge for both particle types which was
slightly reduced, but still negative, when the particles were
suspended in unsupplemented RPMI medium (Figure 1).
Expression of endocytotic uptake proteins in
both cell types
In order to define particle uptake routes, it is crucial in the first
step to determine the presence of the endocytotic proteins which
are involved in endocytosis in both cell types (Figure 2). To
achieve this, laser scanning microscopy (LSM) was applied as
the primary tool for this investigations. Flotillin-1 and clathrin
heavy chain could be visualized in J774A.1 cells, but caveolin-1
was not detected. Clathrin heavy chain was detected within the
cells, both at the cell membrane and in the cytosol. Flotillin-1
was, however, only observed in the cytosol. In A549 cells,
clathrin heavy chain and caveolin-1 were located in the cells
both at the cell membrane as well as in the cytoplasm, albeit to
a lower extent than in the macrophages. Flotillin-1 could not be
detected in A549 cells.
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Table 1: Analysis of the different endocytotic inhibitors regarding specificity and efficiency.
J774A.1 cells
Inhibitors c (µM) Exposure (t) Transferrin Ctx-b 1 µm PS Cell morph.a
Chlorpromazine
(clathrin)
100 30 min No inhibition No inhibition No inhibition –
MDC (clathrin) 250 1 h 30 min Inhibition No inhibition No inhibition +
MβCD (clathrin,
caveolin)
10·103 30 min No inhibition No inhibition No inhibition +
CytoD (phag.,
macrop)
4 1 h 30 min No inhibition No inhibition Inhibition +
A549 cells
Inhibitors c (µM) Exposure (t) Transferrin Ctx-b 1 µm PS Cell morph.a
Chlorpromazine
(clathrin)
100 30 min Inhibition No inhibition No inhibition +
MDC (clathrin) 250 1 h 30 min No inhibition No inhibition No inhibition –
MβCD (clathrin,
caveolin)
10·103 30 min Inhibition Inhibition No inhibition +
CytoD (phag.,
macrop.)
4 1 h 30 min No inhibition No inhibition No inhibition –
aCell morphology: no cellular impairment (+) and cellular damage (-).
Figure 2: LSM images demonstrate the presence of the different
endocytotic uptake proteins within J774A.1 macrophages and A549
epithelial cells. The LSM images show the presence of endocytotic
proteins clathrin heavy chain, caveolin-1 and flotillin-1 in J774A.1 cells
and A549 cells. The white arrows in the upper panel of each image
(XY orthogonal plane) represent the position of the XZ slice shown in
the lower picture. The apical side of the cells corresponds to the
bottom line of the images. Endocytotic uptake proteins are shown in
green and the actin cytoskeleton in red. Scale bar: 8 µm.
Endocytotic inhibitors
With the knowledge of the presence of specific uptake proteins,
it is now feasible to elaborate on the different uptake routes in
each cell type by applying different chemical inhibitors.
Inhibitors of clathrin- and caveolin-mediated endocytosis or
macropinocytosis and phagocytosis were tested for their
optimal concentration, exposure time and cell impairment in
both cell types (Table 1 and Figure 3). The cell morphology was
assessed by LSM (Figure 3) and the cytotoxicity by lactate
dehydrogenase (LDH) assay (see Figure S1, Supporting Infor-
mation File 1). Trypan blue staining marked the integrity of the
cell membrane for cells which were impaired by the inhibitor
(red insets, Figure 3) and revealed the following percentage of
dead cells for J774A.1 cells (n = 3): negative control 20% (SD
± 9.5%), triton 100% (SD ± 0%), chlorpromazine 46.1% (SD ±
2.7%). For A549 cells, the following percentages of dead cells
were revealed: negative control 0% (SD ± 0%), triton 100%
(SD ± 0%), MDC 78.3% (SD ± 15.5%), cytochalasin D 10.3%
(SD ± 9.6%). Fluorescently labelled transferrin was used
together with specific inhibitors as a control to investigate
clathrin-mediated endocytosis and fluorescent ctx-b with inhibi-
tors as a control to analyze caveolin-mediated endocytosis.
Polystyrene particles of 1 µm diameter were used to demon-
strate the inhibition of phagocytosis. The uptake of fluores-
cently labelled transferrin was blocked by applying 250 µM
MDC in J774A.1 cells, whereas MDC could not inhibit
clathrin-mediated endocytosis in A549 cells. In addition, treat-
ment of A549 cells with MDC resulted in cell impairment as
shown by LSM (Figure 3). Chlorpromazine did not inhibit
transferrin uptake and also severely impaired the morphology of
the J774A.1 cells. However, 100 μM chlorpromazine inhibited
the clathrin-mediated endocytosis of A549 cells. Mβcd could
neither inhibit transferrin (clathrin-mediated) nor ctx-b (cave-
olin-mediated) uptake by J774A.1 macrophages. On the
contrary, 10 mM mβcd inhibited clathrin- as well as caveolin-
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mediated endocytosis as shown by the lack of intracellular fluo-
rescently labelled transferrin and ctx-b in A549 cells. The actin
polymerization inhibitor cytochalasin D prevented particle
uptake (d = 1 µm) by J774A.1 cells at a concentration of 4 µM.
Uptake of transferrin by J774A.1 cells could not be prevented
by cytochalasin D (data not shown). In A549 cells, cytocha-
lasin D impaired the cell morphology at all tested concentra-
tions from 5 µM to 10 µM. A lower concentration of 3 µM did
not inhibit particle uptake (data not shown). It is important to
mention that inhibition of cells with cytochalasin D cannot
distinguish between phagocytosis and macropinocytosis.
Fluorescence intensity profiles
To identify in which protein uptake compartments the NPs (d =
40 nm) are present, it is possible to analyze their regions of
fluorescence overlap. Several intensity profiles reveal a distinct
overlap (Figure 4A) of clathrin heavy chain and a signal from
40 nm NPs in J774A.1 cells (Figure 4A, region 1). However,
cases of dissimilarities between the two fluorescence signals
were also recorded (Figure 4A, region 2). Analogous observa-
tions (both in agreement and disagreement) of the flotillin-1
fluorescence signal and 40 nm PS NPs were made (Figure 4B,
regions 1 and 2). These findings were supported by the resulting
Pearson coefficient value found for each region analyzed. Inten-
sity profile plots of subcellular events in A549 cells were not
performed due to a lower expression of the uptake proteins in
these cells compared to the J774A.1 cells.
Particle uptake by the two cell types in the
presence of endocytotic uptake inhibitors
In order to resolve the uptake routes for the given particle size,
both particles were tested together with the optimal inhibitor
concentration for both cell types. Conditions were chosen such
that the uptake of the relevant control substance was completely
inhibited and no impaired cell morphology was observed. Both
cell lines were exposed to either 1 µm PS particles or 40 nm PS
NPs at a concentration of 20 µg/mL for 1 hour either after
preincubation with endocytotic inhibitors (preinhibition experi-
ment) or in coexposure (continuous experiment) with endocy-
totic inhibitors (chlorpromazine, MDC, mβcd, cytochalasin D or
none). Intracellular particles were visualized by LSM
(Figure 5).
Particle uptake evaluation
After 1 hour of incubation, intracellular particles and NP events
(either agglomerates or single NPs, which cannot be distin-
guished by LSM) were visualized in both J774A.1 and A549
cells (Figure 5 and Figures S2 and S3, Supporting Information
File 1). In control cells that were not treated with any inhibitors,
uptake of NPs was observed within only a few minutes in both
cell types (Figure 5). These observations are supported by live
Figure 3: Investigation of cell morphology after inhibitor treatment.
Healthy cells (green inset) retained their cellular structure after inhibitor
treatment. Impaired cells (red inset) showed membrane damage, loss
of integrity and loss of viability. (A) chlorpromazine, (B) monodansylca-
daverine, (C) mβcd, and (D) cytochalasin D. Scale bar: 10 µm.
cell imaging, which revealed that NP uptake is a very fast
process, starting 5 to 10 minutes after exposure to the cells
(Figures S2 and S3, Supporting Information File 1). Uptake of
1 µm particles was only observed in J774A.1 macrophages but
not in A549 epithelial cells for the given exposure time of
1 hour. A549 cells required a much longer time of 1 hour to
internalize 1 µm particles (data not shown). However, since the
inhibitors began to induce cell damage after 1 to 1.5 hours,
observation time could not be extended. In J774A.1 cells, MDC
Beilstein J. Nanotechnol. 2014, 5, 1625–1636.
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Figure 4: Fluorescence intensity profiles of J774A.1 cells, 40 nm PS NPs with clathrin heavy chain or flotillin-1. (A) and (B) are confocal images of
J774A.1 cells treated with 40 nm PS NPs (red) and primary antibodies against uptake proteins (green), respectively. The corresponding relative fluo-
rescence profiles of the overlapping signals are shown in the diagrams to the right (regions 1 and 2). Cells are shown in the transmission light
channel. The Pearson coefficient (rp) was calculated for each of the regions. (A) 40 nm PS NPs and clathrin heavy chain, (B) 40 nm PS NPs and
flotillin-1. The white arrows are 6.8 µm in length. Scale bar = 10 µm.
partially inhibited the uptake of 40 nm NPs (Figure 5). A
significant fraction of the 40 nm particles was observed outside
at the cell membrane (Figure S2, Supporting Information
File 1). However, NPs were also detected within the cells
(Figure 5). Cytochalasin D also partially blocked the uptake of
NPs. The uptake of 1 µm particles by J774A.1 was completely
blocked by cytochalasin D, whereas MDC had no effect.
Although most 40 nm NP events were located outside of the
cells, intracellular particle events could still be detected in both
chlorpromazine-treated and mβcd-treated A549 cells. The 1 µm
particles were not observed inside the epithelial cells under any
condition (Figure 5).
Discussion
For any future biomedical application of engineered NPs, it is
mandatory to fundamentally understand their interaction with
living systems. The cellular uptake pathway of a NP will have
direct consequences on its intracellular localization; hence,
understanding the overall NP distribution in a specific compart-
ment, such as endosomes, lysosomes or others, might provide
some interesting suggestions for developing a future drug
delivery system. To gain more insight into the uptake mecha-
nism(s) of NPs in comparison to larger (i.e., micron-size) parti-
cles of the same material, a broad array of chemical inhibitors
was used that were shown to inhibit certain endocytotic mecha-
nisms [52-54]. All particle exposure experiments were
conducted in serum-free medium in order to avoid binding of
serum proteins to the particle surfaces which might induce
agglomeration, however, the binding of small molecules or salts
in the cell culture medium cannot be excluded.
The focus of the present study was on two cell types that have
important clearing and barrier functions, namely, macrophages
(represented by the mouse J774A.1 macrophage cell line) and
epithelial cells (represented by the A549 human alveolar epithe-
lium cell line). First, the specificity of the different inhibitors
was assessed for both cell types. As a second step, the opti-
mized inhibitors were used to study the uptake of the two
different particle types. Visualization of the fluorescently
tagged particles was done by LSM. LDH measurements
revealed no cytotoxicity for the combined inhibitors and endo-
cytotic protein markers for both cell types being analyzed.
Additionally, inhibitors which negatively affected the cells are
summarized in Table 1 and the images in Figure 3 are presented
with either red (impairment by inhibitor) or green (no effect by
inhibitor) letter insets. Trypan blue staining demonstrated the
same outcome. The percentage of dead cells which were treated
with cytochalasin D was not as high as expected for A549 cells.
This could be due to cytochalasin D blocking actin polymeriza-
tion and hence preventing Trypan blue from entering the cells,
although the cells are severely affected by this inhibitor.
Beilstein J. Nanotechnol. 2014, 5, 1625–1636.
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Figure 5: Laser scanning microscopy imaging revealed particle uptake in J774A.1 and A549 cells. (A–C) Uptake of 40 nm PS NPs (NP: red, cytosol:
grey). (A) Untreated cells with 40 nm NPs. (B) 40 nm NPs and cytochalasin D (cytoD) in J774A.1 and chlorpromazine (cpz) in A549 cells. (C) 40 nm
NPs and monodansylcadaverine (mdc) in J774A.1 cells and methyl-β-cyclodextrin (mβcd) in A549 cells. (D) Negative control. (E–G) Uptake of 1 µm
PS particles (particles: green, cytosol: grey). (E) Untreated cells with 1 µm particles. (F–G) 1 µm particles with the same adequate inhibitors. Scale
bar: 5 µm. White arrows represent intracellular events of 1 µm particles in J774A.1 cells. The negative controls have a scale bar of 10 µm.
It was shown that the optimal and desired function of the endo-
cytotic inhibitors was occasionally different in the two cell
types, namely, the A549 epithelial cells and J774A.1
macrophages. The inhibition studies were carried out within
1 hour, since endocytotic processes were very fast [20,55,56]
and the inhibitors also began to impair the cells in their
morphology after a longer incubation time. For each of the two
cell types, the exposure time and concentration to achieve
optimal inhibition had to be defined. This careful optimization
for each inhibitor and each cell type is very often missing in
many published studies. This balancing act between the desired
functional inhibition of a specific pathway and the possible
adverse effects on the cells did not always provide an appli-
cable result. For instance, for some of the inhibitors the concen-
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trations had to be very high for an efficient inhibition but then
in this case they strongly impaired the cells. mβcd also inhib-
ited the uptake of transferrin (clathrin-mediated endocytosis) in
A549 cells [57], however, mβcd had detrimental effects on the
J774A.1 cell morphology and could only be exposed for a
limited period of 30 minutes preincubation [32].
In J774A.1 macrophages, macropinocytosis and phagocytosis
could be optimally inhibited by cytochalasin D and MDC which
could efficiently block clathrin-mediated endocytosis. However,
optimal conditions for the inhibition of the lipid raft-mediated
pathway in this cell type could not be established. mβcd has
been described to be an optimal inhibitor of lipid raft-mediated
endocytosis. Therefore it was rather surprising that it did not
work in the J774A.1 cells, also because flotillin-1 was highly
expressed in all cells as shown by LSM. However, the
localization of the protein was mainly intracellular and
caveolin-1 was not present at all. This finding should be evalu-
ated more thoroughly. In addition, other inhibitors such as
statins, filipin or nystatin could be used, however, severe cell
damage for those three inhibitors has been observed in earlier
studies [32].
In A549 epithelial cells, the macropinocytosis and phagocy-
tosis pathways could not be explored, as the uptake of 1 µm
particles by these cells was never observed, even under
controlled conditions. Surprisingly, these findings are in contra-
diction to other studies that have shown uptake of such parti-
cles [30,58]. However, these A549 cells were used in a triple
cell coculture system combined with macrophages and dendritic
cells. Therefore, the results are not directly comparable. In add-
ition, the uptake was evaluated only within 1 hour, and phago-
cytosis/macropinocytosis might be slower in epithelial cells
than in macrophages. Therefore, longer incubation times should
be applied in future studies, but also at optimal conditions under
which the inhibitors do not induce adverse cell effects. The
clathrin-mediated endocytosis was impeded by 100 μM chlor-
promazine. Also, 10 mM mβcd was shown to block caveolin-
mediated endocytosis with the restriction of a maximum of
30 minutes exposure in the inhibitor. Consequently, this cell
line seems to be capable of ingesting particles by clathrin- as
well as caveolin-mediated endocytosis. This is underlined by
the presence of clathrin heavy chain and caveolin-1 in the cyto-
plasm and at the cell membrane. Interestingly, these cells do not
show flotillin-1 compared to the J774A.1 cells. Nonetheless, the
role of this protein on NP uptake will need to be further evalu-
ated in the future.
It is obvious from these results that the inhibitors have different
effects depending on the cell type. The reasons for this observa-
tion can be many: the genotypic and phenotypic differences
between the cell types as well as species differences (i.e., the
macrophages are a mouse cell line, while the epithelial cells are
human) play a role. Hence, a preliminary study to optimize the
use of inhibitors with each cell type should be a prerequisite for
every future investigation involving endocytotic pathway
inhibitors. To summarize, one can say that each cell type reacts
differently to the applied inhibitors and possess different uptake
routes.
Regarding the (nano) particle uptake study, cytochalasin D
completely blocked the uptake of 1 µm particles via phagocy-
tosis and macropinocytosis in J774A.1cells [59]. Since cytocha-
lasin D did not inhibit the uptake of transferrin and ctx-b, strong
evidence is provided that this inhibitor did not severely affect
other endocytotic pathways as also observed by others [60]. A
decreased uptake of 40 nm NPs and accumulation of NPs at the
cell surface in the presence of cytochalasin D was observed.
This could also be due to the formation of agglomerates on the
cellular surface that would then show similar physio-chemical
behavior as micron-size particles. Since accumulation at the cell
border of 40 nm NPs was observed prior to actin-driven uptake,
we argue that phagocytosis or macropinocytosis is involved in
both the uptake of larger aggregates of 40 nm NPs and 1 µm
particles. Our findings are in agreement with other studies that
showed a reduced uptake of 40 nm carboxylated polystyrene
particles in HeLa and 1321N1 cells in the presence of cytocha-
lasin A [52] and by cytochalasin D in pulmonary macrophages
[59]. In addition, the inhibition of 40 nm NP uptake also
occurred in the presence of the clathrin inhibitor MDC in
J774A.1 cells. This suggests that J774A.1 macrophages can
employ multiple uptake mechanisms for the endocytosis of
40 nm PS NPs by both clathrin-mediated as well as
macropinocytosis or phagocytosis. Caveolin-mediated uptake
was not observed, since mβcd did not block the uptake of
transferrin. Moreover, the related proteins such as caveolin-1
and flotillin-1 were not detected at the cell border. As already
known, caveolin-mediated endocytosis is mainly observed in
several cell types including capillary endothelium, type I
alveolar epithelial cells, smooth muscle cells and fibroblasts
[20]. Therefore, this result supports the cell type specific mech-
anism of this uptake.
The colocalization of clathrin heavy chain and the 40 nm PS NP
fluorescence in the profile plots are also a strong hint for the
involvement of a clathrin-mediated pathway in the uptake of
40 nm PS NPs by J774A.1. However, there were regions where
40 nm NPs did not colocalize with the clathrin heavy chain
signal. The LSM data showed that J774A.1 cells express
flotillin-1, and indeed profile plots of flotillin-1 have shown a
colocalization with the 40 nm NPs [61]. It was shown that the
phagosome proteome of J774A.1 cells contains high amounts of
Beilstein J. Nanotechnol. 2014, 5, 1625–1636.
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flotillin-1 [62]. However, all tested inhibitors for lipid raft-
mediated uptake failed with this cell type. In addition,
caveolin-1 was not detected. Therefore, the role of this uptake
mechanism is still not clear in this cell and for this particle type.
It also has been shown that caveolin-1 was only rarely present
in human macrophages [62]. Consequently, one can conclude
that NPs are taken up by a different mechanism in this cell type,
which might also depend on the agglomeration behavior of
particles on the cell surface, and thus the “secondary” size of
the particles. Neither chlorpromazine nor mβcd (i.e., blocking
the clathrin-mediated and the caveolin-mediated pathway) could
fully inhibit the uptake of 40 nm NPs in A549 cells, since intra-
cellular particle events could still be detected after treatment
with those two inhibitors. Thus, A549 may also employ
multiple endocytotic pathways, as it is known that different
pathways can be used [52].
Finally, LSM was used (for exact spatial localization) to
analyze the interaction of fluorescently labelled particles with
single cells. This method is crucial since one can visually distin-
guish between extracellular and intracellular particle events. We
also have attempted to quantify the uptake of the particles by
fluorescence activated cell sorter (FACS). However, it was
observed that the use of endocytotic pathway inhibitors resulted
in particle agglomerates that were attached to the outer cell
membrane which remained even after extensive washing.
Therefore, FACS could not be used in combination with
inhibitory conditions.
All particles internalized by endocytotic pathways are finally
localized in intracellular vesicles. However, some other studies
have shown that NPs of different materials were detected in the
intracellular space and/or free in the cytoplasm. Since they were
not membrane-bound, alternative uptake routes for cellular
uptake might exist [22,46,59,63]. Possible uptake mechanisms
such as receptor mediated diffusion via membrane pores as well
as passive uptake by van der Waals or steric interactions
(subsumed as adhesive interactions) [64,65] were proposed by
the authors of these studies.
Conclusion
It was shown that the particle size is critical in determining
which endocytotic uptake route is deployed, and additionally,
this process is cell type dependent. Not all inhibitors blocked
the related pathway in the two different cell lines in the same
way, which is also in agreement with the expected uptake
mechanism per cell type. Therefore, each condition must be
evaluated with the use of positive markers. A549 cells did not
take up any 1 µm PS particles by phagocytosis/macropinocy-
tosis over a period of 1 hour, whereas 40 nm NPs were ingested
by clathrin- as well as caveolin-endocytotic pathways.
In J774A.1 cells, 1 µm particles were engulfed by phagocytosis/
macropinocytosis and 40 nm PS NPs by both clathrin-mediated
as well as macropinocytosis or phagocytosis. Therefore, it
seems that both cell types take up NPs by different mechanisms,
although the mechanisms are not similar for the different cell
types.
Experimental
Cell cultures
Human alveolar epithelial type II cells (A549 cell line) and
mouse macrophage cells (J774A.1 cell line), both from Amer-
ican tissue Type Culture Collection, were cultured in RPMI
1640 with HEPES (Gibco, Luzern, Switzerland) completed with
10% foetal bovine serum (heat inactivated, PAA Laboratories,
Austria), 1% L Glutamine (Gibco, Luzern, Switzerland) and 1%
penicillin/streptomycin (Gibco, Luzern, Switzerland) and kept
at 37 °C and 5% CO2. The A549 epithelial cells were split twice
per week using trypsin (0.05% trypsin-EDTA, GIBCO, Switzer-
land). J774A.1 cells were sub-cultured using the scraping
method, resuspended in the medium and finally centrifuged
(2 min, 2000 rpm and 21 °C). A549 cells were seeded at a
density of 35 × 103 cells/mL and J774A.1 cells at a density of
25 × 104 cells/mL in BD FalconTM 4 chamber polystyrene
vessels with tissue culture treated glass slide with a growth area
of 1.7 cm2 (Milian, Geneva, Switzerland). A549 cells were
grown to confluence for 7 days prior to exposure experiments
and J774A.1 cells for 1 day and allowed to adhere prior to use.
Particle characterization and exposure
The commercially available carboxylate Fluoresbrite™ plain
yellow green (cataloged as 1 µm hydrodynamic diameter) and
red (cataloged as 40 nm hydrodynamic diameter) polystyrene
(PS) particles (Molecular Probes, Luzern, Switzerland) were
used for the study. The particles were characterized in terms of
size by dynamic light scattering (DLS) and transmission elec-
tron microscopy (TEM). The hydrodynamic radius was
acquired by DLS (3D LS Spectrometer, LS Instruments AG,
Fribourg, Switzerland) based on a viscosity of 0.89 mPas and a
refractive index of 1.33. The correlation function was measured
at a scattering angle of 90° at T = 25 °C. The data was analyzed
with a fitting routine applying a single exponential model and
accounting for polydispersity assuming a Schulz–Zimm distrib-
ution. Both particles were measured at a concentration of
20 µg/mL in either unsupplemented RPMI medium or dH2O
over a time window of 1 hour.
The particles were observed with a Hitachi transmission elec-
tron microscope (H-7100, Tokyo, Japan) operating at an accel-
eration voltage of 75 kV and equipped with a Morada CCD
digital camera (Olympus, Tokyo, Japan). Size distributions of
both PS particle types were obtained by image analysis using
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Fiji software. Thereby, images were converted to binary images
by automated thresholding (default threshold) and analyzed
applying an ellipse fit. A total of 982 counts were performed for
the NPs and 102 counts were collected for the micron-sized
particles. The electrophoretic mobility of the particles was
determined by electrophoresis (Brookhaven 90 Plus Instru-
ments Corp., Holtsville, USA). The measured particle mobility
in the electric field was transformed to the zeta potential by
applying the Smoluchowski model. The small particles were
measured at a concentration of 60 µg/mL and the larger parti-
cles at 20 µg/mL.
Prior to the cell exposure, all particle suspensions were soni-
cated for 2 minutes in order to avoid aggregation. Polystyrene
particles were suspended in RPMI 1640 medium and adjusted
to a concentration of 20 µg/mL. A 1 mL particle suspension
was applied on a growth area of 1.7 cm2 and the cells were
exposed for 1 hour in the well.
Endocytotic uptake proteins
Antibodies against clathrin heavy chain, flotillin-1 and
caveolin-1 (all fluorescently labelled with Alexa Fluor 488,
antibodies-online GmbH, Aachen, Germany) were used at a
final dilution of 1:20 in 1× PBS on fixed cells. After 1 hour of
staining (in a dark room at room temperature) and three
washing cycles with 1× PBS, the cells were mounted using
medium Glycergel mounting medium (C0563, Dako, Baar,
Switzerland). The intensity profiles were performed using Fiji
software. The pearson coefficient (rp) reavealed the colocaliza-
tion/signal overlap of endocytotic uptake proteins and NPs for
all analyzed regions.
Inhibition of endocytosis
Different endocytotic inhibitors were tested for their optimal
concentration, exposure time and cell impairment (Table 1,
Figure 3). Inhibition of clathrin-mediated endocytosis in both
cell types was tested with chlorpromazine hydrochloride
(C8138, Sigma-Aldrich, Switzerland) and monodansylcadav-
erine (Dansylcadaverine, D4008, Sigma-Aldrich). Inhibition of
caveolin-mediated endocytosis was performed in both cell lines
using 10 mM methyl-β-cyclodextrin (mβcd) (C4555, Sigma-
Aldrich). A 4 µM cytochalasin D (C8273, Sigma-Aldrich) solu-
tion was used to inhibit phagocytosis and macropinocytosis in
both cell lines.
Cell treatment
Both cell types were preincubated for 30 minutes and subse-
quently exposed to either the control substances (i.e., transferrin
or ctx-b) or the PS particles, or in combination with the
inhibitor (for continuous inhibition). Exposures were carried out
for 1 hour.
Control experiments
Alexa fluor 488 coated transferrin (T13342, Invitrogen),
dissolved in dH2O containing 1% NaN3 and diluted in RPMI to
a final concentration of 120 μg/mL, was used to test the inhibi-
tion of clathrin-mediated endocytosis. Cholera toxin subunit-b
(ctx-b) labelled with Alexa Fluor 488 conjugate (C34775,
Molecular Probes) was used to test inhibition of caveolin-medi-
ated endocytosis. Ctx-b was dissolved in 10 mM phosphate-
buffered saline (PBS, pH 7.4) containing 1% NaN3 and diluted
to a final concentration of 0.6 μg/mL 1× PBS (pH 7.4) in RPMI
prior to use. To test macropinocytosis and phagocytosis, 1 µm
carboxylate modified fluospheres (molecular probes) were used
at a concentration of 20 µg/mL in RPMI.
Laser scanning microscopy of fixed and living
cells
For LSM imaging, the cells were fixed with 3% paraformalde-
hyde (PFA, Sigma-Aldrich, Switzerland) in PBS for 15 minutes
at room temperature. The cells were then washed with 1× PBS,
then permeabilized for 15 minutes with 0.2% Triton X and then
washed again with 1× PBS. The F-actin cytoskeleton was
stained with rhodamine phalloidin (Invitrogen, Luzern, Switzer-
land) at a dilution of 1:50 in 1× PBS. Following this step, the
cells were then washed and mounted in glycergel mounting
medium (C0563, Dako, Baar, Switzerland). Image acquisition
was performed with an inverted Zeiss LSM 710 Meta (Axio
Observer.Z1, Zeiss, Switzerland) microscope equipped with
405, 488 and 561 nm laser excitation sources. Fields of inter-
ests were acquired at 5 different randomly selected areas per
glass slide. The experiment was performed using a 63x/N.A 1.4
immersion oil lens. Cellular and morphological information was
retrieved using Imaris software (Bitplane 7.4, Zürich, Switzer-
land).
For live cell imaging, the cells were seeded in a Lab-TekTM II
chambered coverglass 4 chamber well (1.5 german coverglass
system, NC-155382, Nunc, Milian, Geneva, Switzerland),
stained with Cell trackerTM violet BMQC dye and incubated for
1 hour at 37 °C and 5% CO2 followed by three washing steps
with 1× PBS. Finally, transparent RPMI 1640 medium (no 1%
L-glutamine, no antibiotics, no fetal calf serum and without
phenol red pH indicator) was added with either 40 nm or 1 µm
polystyrene particles alone or in combination with the inhibitor,
and time lapse imaging was started. The live cell imaging ran
over a time period of 60 minutes during which the cells were
kept in a constant environmental at 37 °C and 5% CO2. Image
acquisition was performed as described above.
Lactate dehydrogenase (LDH) assay
A 1 mL sample of the supernatant of each experiment was
collected and stored at 4 °C to determine cytotoxicity. Triton X
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(0.2% in unsupplemented RPMI) was used for cell lysis as a
positive control. The supernatant of untreated cells was used as
negative control. The LDH assay was performed with the Cyto-
toxicity Detection Kit (Roche Applied Science, Mannheim,
Germany) according to the supplier's manual. Each supernatant
was measured in triplicate. All measurements were analyzed as
n = 3 experiments.
Trypan blue exclusion assay
The assay was carried out according to the manufacturer’s
manual (Sigma-Aldrich, Steinheim, Germany). Trypan was
added to untreated cells and to cells which showed impairment
by the inhibitors (Table 1). At a dilution of 1:2 in trypan blue,
the cells were stained and counted in a Neubauer chamber (Blau
Brand, Ref. 717805, Wertheim, Germany). The positive control
was performed by adding 0.2% Triton X to the cells for
5 minutes, prior adding trypan blue. All measurements were
analyzed as n = 3 experiments.
Supporting Information
Supporting Information File 1
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